| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ronnachai Kongsakon, Thawatchai Leelahanaj, Natalia Price, Liesl Birinyi-Strachan, Peter Dave. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. vol 88. issue 9. 2006-05-04. PMID:16536115. |
to compare the annual costs of treating schizophrenia with four atypical antipsychotics-olanzapine, risperidone, quetiapine and ziprasidone and one typical antipsychotic: haloperidol in thailand |
2006-05-04 |
2023-08-12 |
Not clear |
| Guido Grass, Martin Hellmich, F Markus Lewek. Clozapine alone versus clozapine and risperidone for refractory schizophrenia. The New England journal of medicine. vol 354. issue 17. 2006-05-03. PMID:16641404. |
clozapine alone versus clozapine and risperidone for refractory schizophrenia. |
2006-05-03 |
2023-08-12 |
Not clear |
| Herbert Y Meltzer, A Elif Anil Yağcioğlu, Berna Binnur Kivircik Akded. Clozapine alone versus clozapine and risperidone for refractory schizophrenia. The New England journal of medicine. vol 354. issue 17. 2006-05-03. PMID:16642583. |
clozapine alone versus clozapine and risperidone for refractory schizophrenia. |
2006-05-03 |
2023-08-12 |
Not clear |
| Stanton L Gerso. Clozapine alone versus clozapine and risperidone for refractory schizophrenia. The New England journal of medicine. vol 354. issue 17. 2006-05-03. PMID:16642587. |
clozapine alone versus clozapine and risperidone for refractory schizophrenia. |
2006-05-03 |
2023-08-12 |
Not clear |
| Richard S E Keefe, Carrie A Young, Stephanie L Rock, Scot E Purdon, James M Gold, Alan Breie. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia research. vol 81. issue 1. 2006-05-02. PMID:16202565. |
one-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. |
2006-05-02 |
2023-08-12 |
Not clear |
| Richard S E Keefe, Carrie A Young, Stephanie L Rock, Scot E Purdon, James M Gold, Alan Breie. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia research. vol 81. issue 1. 2006-05-02. PMID:16202565. |
four hundred and fourteen inpatients or outpatients with schizophrenia and schizoaffective disorder were treated with oral olanzapine (n = 159), risperidone (n = 158), or haloperidol (n = 97). |
2006-05-02 |
2023-08-12 |
Not clear |
| Robert W Kerwin, Anusha A Bolonn. Is clozapine antisuicidal? Expert review of neurotherapeutics. vol 4. issue 2. 2006-04-25. PMID:15853559. |
preliminary reports indicate improvements in suicidality in schizophrenia patients treated with other modern atypical antipsychotics, for example olanzapine [zyprexa], risperidone [risperdal] and sertindole [serdolect], but further investigation is required to clarify their role as antisuicidal drugs. |
2006-04-25 |
2023-08-12 |
Not clear |
| J P Lindenmayer, Anzalee Kha. Pharmacological treatment strategies for schizophrenia. Expert review of neurotherapeutics. vol 4. issue 4. 2006-04-20. PMID:15853589. |
the pharmacological choices for the treatment of schizophrenia have been greatly expanded with the availability of the atypical compounds clozapine (clozaril, novartis), risperidone (risperdal, janssen-cilag), olanzapine (zyprexa, eli lilly & co.), quetiapine (seroquel, astrazeneca), ziprasidone (geodon, pfizer inc.) and aripiprazole (abilify, otsuka pharmaceutical co. ltd). |
2006-04-20 |
2023-08-12 |
Not clear |
| b' Andr\\xc3\\xa1s Klebovich, Zolt\\xc3\\xa1n Bujdos\\xc3\\xb3, Andrea Mesk\\xc3\\xb3, Rom\\xc3\\xa1na Zelk\\xc3\\xb. Comparison of olanzapine and risperidone use in psychiatric rehabilitation. Therapie. vol 60. issue 6. 2006-04-20. PMID:16555495.' |
because olanzapine and risperidone have similar efficacy and tolerability in the treatment of schizophrenia and these two agents are the most widely used atypical antipsychotics in hungary, the utilisation of the drugs is a relevant consideration. |
2006-04-20 |
2023-08-12 |
Not clear |
| Bruce L Lambert, Chia-Hung Chou, Ken-Yu Chang, Eskinder Tafesse, William Carso. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiology and drug safety. vol 14. issue 6. 2006-04-19. PMID:15786516. |
to examine the risk of developing type 2 diabetes mellitus among people with schizophrenia exposed to atypical antipsychotics (clozapine, olanzapine, quetiapine, risperidone) compared to those exposed to conventional antipsychotics. |
2006-04-19 |
2023-08-12 |
Not clear |
| Hans-Jürgen Mölle. Risperidone: a review. Expert opinion on pharmacotherapy. vol 6. issue 5. 2006-04-14. PMID:15934906. |
the following review gives an overview of the huge clinical database available for risperidone in the field of schizophrenia. |
2006-04-14 |
2023-08-12 |
Not clear |
| Vicente Molina, Santiago Reig, Javier Sanz, Tomás Palomo, Carlos Benito, Javier Sánchez, Fernando Sarramea, Javier Pascau, Manuel Desc. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophrenia research. vol 80. issue 1. 2006-04-14. PMID:16150576. |
thus, treatment with risperidone and clozapine in schizophrenia may have an effect on gray and white matter volume and needs further exploration. |
2006-04-14 |
2023-08-12 |
Not clear |
| Sophie Rémillard, Emmanuelle Pourcher, Henri Cohe. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophrenia research. vol 80. issue 1. 2006-04-14. PMID:16162401. |
risperidone, an atypical nlp, has been reported to improve executive function in schizophrenia (sz), but there is controversy regarding these findings. |
2006-04-14 |
2023-08-12 |
human |
| Jonathan M Meyer, Gahan Pandina, Cynthia A Bossie, Ibrahim Turkoz, Andrew Greenspa. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clinical therapeutics. vol 27. issue 12. 2006-04-11. PMID:16507379. |
effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. |
2006-04-11 |
2023-08-12 |
Not clear |
| A Mané, I Baeza, A Morer, M L Lázaro, M Bernard. Neuroleptic malignant syndrome associated with risperidone in a male with early-onset schizophrenia. Journal of child and adolescent psychopharmacology. vol 15. issue 6. 2006-04-03. PMID:16379503. |
neuroleptic malignant syndrome associated with risperidone in a male with early-onset schizophrenia. |
2006-04-03 |
2023-08-12 |
Not clear |
| Leslie A Lenert, Marcia F T Rupnow, Christine Elnitsk. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health and quality of life outcomes. vol 3. 2006-03-31. PMID:16153308. |
the objective of this study was to apply a disease-specific utility mapping function for schizophrenia to data from a large, 1-year, open-label study of long-acting risperidone and to compare its performance with an sf-36-based utility mapping function. |
2006-03-31 |
2023-08-12 |
Not clear |
| Niina Ezewuzie, David Taylo. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. Journal of psychopharmacology (Oxford, England). vol 20. issue 1. 2006-03-29. PMID:16174679. |
establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. |
2006-03-29 |
2023-08-12 |
Not clear |
| Niina Ezewuzie, David Taylo. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. Journal of psychopharmacology (Oxford, England). vol 20. issue 1. 2006-03-29. PMID:16174679. |
we aimed to establish the dose-response relationship for oral risperidone in relapsed schizophrenia. |
2006-03-29 |
2023-08-12 |
Not clear |
| Niina Ezewuzie, David Taylo. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. Journal of psychopharmacology (Oxford, England). vol 20. issue 1. 2006-03-29. PMID:16174679. |
three studies used fixed doses of oral risperidone for eight weeks in relapsed schizophrenia. |
2006-03-29 |
2023-08-12 |
Not clear |
| Niina Ezewuzie, David Taylo. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. Journal of psychopharmacology (Oxford, England). vol 20. issue 1. 2006-03-29. PMID:16174679. |
the optimal dose of risperidone in relapsed schizophrenia is 4 mg daily. |
2006-03-29 |
2023-08-12 |
Not clear |